Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody

Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody

<b>: </b>Invariant natural killer T cells (iNKTs) directly kill tumor cells and trans-activate the anti-tumor functions of dendritic cells (DC), natural killer (NK) cells, and T and B cells. As such, iNKTs serve as a powerful tool for use in cell-based cancer immunotherapy. iNKT cell act...

Full description

Bibliographic Details
Main Authors: Nishant P. Patel, Peng Guan, Devika Bahal, Tanwir Hashem, Felix Scheuplein, Robert Schaub, Kim E. Nichols, Rupali Das
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:International Journal of Molecular Sciences
Subjects:
antitumor immunity
monoclonal antibody
NKTT320
invariant natural killer T cells
immunotherapy
Online Access:https://www.mdpi.com/1422-0067/21/12/4317

Similar Items

Similar Items